Results 21 to 30 of about 15,200 (191)

Bone marrow senescence and the microenvironment of hematological malignancies [PDF]

, 2020
Senescence is the irreversible arrest of cell proliferation that has now been shown to play an important role in both health and disease. With increasing age senescent cells accumulate throughout the body, including the bone marrow and this has been ...
Bowles, Kristian M., Hellmich, Charlotte, Moore, Jamie A., Rushworth, Stuart A.   +3 more
core   +1 more source

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Therapeutics and Clinical Risk Management, 2023
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Hughes MS, Lentzsch S
doaj  

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot   +7 more
doaj   +1 more source

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma [PDF]

, 2016
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with ...
Abidi, Alexanian, Attal, Attal, Attal, Attal, Attal, Badros, Baldini, Ballestrero, Barlogie, Barlogie, Barlogie, Barlogie, Barlogie, Bartel, Beaven, Berdeja, Berenson, Bernard Maybury, Bladé, Blanes, Cancer Research UK, Cavo, Cavo, Chauhan, Chen, Child, Chérel, Comenzo, Desikan, Dimopoulos, Dispenzieri, Dispenzieri, Donato, Drayson, Durie, Fenk, Fermand, Fermand, Forsberg, Garfall, Garg, Gay, Giralt, Goel, Gordon Cook, Govindarajan, Green, Guy Pratt, Harousseau, Harousseau, Huang, Jakubowiak, Karthik Ramasamy, Kazmi, Kelly, Knop, Kochenderfer, Kumar, Kwee Yong, Lacy, Ladetto, Lahuerta, Lahuerta, Lebovic, Leleu, Lokhorst, Lokhorst, Lonial, Lonial, Ma, Magarotto, Mai, Maiolino, Marin, Mark, Maude, McCann, McCarthy, Mellqvist, Mihara, Mitsiades, Miyamoto, Moreau, Moreau, Moreau, Morgan, Nair, Nath, Nishihori, Nooka, Orchard, Paiva, Palumbo, Palumbo, Pica, Pineda-Roman, Plesner, Popat, Pulte, Qazilbash, Rabin, Rapoport, Rapoport, Rawstron, Riccardi, Rosenblatt, Roussel, Roussel, Rueff, San Miguel, San-Miguel, Sborov, Scheid, Shi, Sonneveld, Sonneveld, Sonneveld, Sonneveld, Spencer, Spencer, Stewart, Stewart, Tacchetti, Voorhees, Zahradova, Zamagni, Zimmerman   +128 more
core   +2 more sources

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells.
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon   +17 more
doaj   +1 more source

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party [PDF]

, 2017
Non peer ...
Beguin, Yves, Chevalier, Patrice, Dubois, Valerie, El-Cheikh, Jean, Fegueux, Nathalie, Finke, Juergen, Francois, Sylvie, Garban, Frederic, Garderet, Laurent, Gluckman, Eliane, Iacobelli, Simona, Koster, Linda, Kroeger, Nicolaus, Lioure, Bruno, Maertens, Johan, Maillard, Natacha, Meijer, Ellen, Michallet, Mauricette, Passweg, Jakob, Petersen, Eefke, Ruggeri, Annalisa, Russell, Nigel, Schipperus, Martin, Sobh, Mohamad, Tabrizi, Reza, Tholouli, Eleni, Van Biezen, Anja, Volin, Liisa, von dem Borne, Peter   +28 more
core   +3 more sources

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma [PDF]

, 2021
Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of programmed death receptor-1 on immune effector cells.
Carson, Robin, Cohen, Yael C., Crist, Wendy, Feng, Huaibao, Fu, Jiayu, Garvin, Wendy, Jackson, Carolyn, Lavi, Noa, Lonial, Sagar, Oriol, Albert, San-Miguel, Jesus, Schecter, Jordan, Vlummens, Philip, Wu, Ka Lung, Xie, Hong   +14 more
core   +1 more source

Immuno-targeting the multifunctional CD38 using nanobody [PDF]

, 2016
published_or_final_versio
Deng, QW, Hao, Q, Hou, YN, Koch-Nolte, F, Lam, MC, Lee, HC, Li, T, Liu, J, Qi, S, Unger, M, Wang, XW, Xin, D, Zhang, H, Zhang, P, Zhao, YJ   +14 more
core   +1 more source

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Journal of Translational Autoimmunity, 2019
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Kristine A. Frerichs, Christie P.M. Verkleij, Patricia W.C. Bosman, Sonja Zweegman, Henny Otten, Niels W.C.J. van de Donk   +5 more
doaj   +1 more source

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
doaj   +1 more source